NIH-led effort launches Big Data portal for Alzheimer’s drug discovery
A National Institutes of Health-led public-private partnership to transform and accelerate drug development achieved a significant milestone today with the launch of a new Alzheimer’s Big Data portal — including delivery of the first wave of data — for use by the research community. The new data sharing and analysis resource is part of the Accelerating Medicines Partnership (AMP), an unprecedented venture bringing together NIH, the U.S. Food and Drug Administration, industry and academic scientists from a variety of disciplines to translate knowledge faster and more successfully into new therapies. The opening of the AMP-AD Knowledge Portal and release of the first wave of data will enable sharing and analyses of large and complex biomedical datasets. Researchers believe this approach will ramp up the development of predictive models of Alzheimer’s disease and enable the selection of novel targets that drive the changes in molecular networks leading to the clinical signs and symptoms of the disease ... Developed by Sage Bionetworks , a Seattle-based non-profit organization promoting open science, the portal will house several waves of Big Data to be generated over the five years of the AMP-AD Target Discovery and Preclinical Validation Project by multidisciplinary academic groups. The academic teams, in collaboration with Sage Bionetworks data scientists and industry bioinformatics and drug discovery experts, will work collectively to apply cutting-edge analytical approaches to integrate molecular and clinical data from over 2,000 postmortem brain samples. The National Institute on Aging (NIA) at NIH supports and coordinates the multidisciplinary groups contributing data to the portal. The AMP Steering Committee for the Alzheimer’s Disease Project is composed of NIA and the National Institute of Neurological Disorders and Stroke, both of NIH, the U.S. Food and Drug Administration, four pharmaceutical companies (AbbVie, Biogen Idec, GlaxoSmithKline and Lilly) and four non-profit groups (Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Geoffrey Beene Foundation and USAgainst Alzheimer’s) and is managed through the Foundation for the NIH ..."